Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
198.32
+6.28 (3.27%)
At close: Aug 15, 2025, 4:00 PM
202.28
+3.96 (2.00%)
After-hours: Aug 15, 2025, 4:36 PM EDT
Company Description
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally.
The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
The company was incorporated in 2006 and is based in Hellerup, Denmark.
Ascendis Pharma A/S
| Country | Denmark |
| Founded | 2006 |
| IPO Date | Jan 28, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,017 |
| CEO | Jan Mikkelsen |
Contact Details
Address: Tuborg Boulevard 12 Hellerup, 2900 Denmark | |
| Phone | 45 70 22 22 44 |
| Website | ascendispharma.com |
Stock Details
| Ticker Symbol | ASND |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 0001612042 |
| CUSIP Number | 04351P101 |
| ISIN Number | US04351P1012 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jan Moller Mikkelsen | President, Chief Executive Officer, Member of Executive Board and Executive Director |
| Scott T. Smith | Chief Financial Officer, Executive Vice President and Member of Executive Board |
| Pedersen Anni Lotte Kirstine Sonderbjerg | Executive Vice President, Chief Administrative Officer and Member of the Executive Board |
| Michael Wolff Jensen L.L.M. | Executive Vice President, Chief Legal Officer and Member of the Executive Board |
| Mads Bodenhoff | Senior Vice President, Head of Finance and Principal Accounting Officer |
| Flemming Steen Jensen | Executive Vice President of Product Supply and Quality |
| Dr. Kennett Sprogoe Ph.D. | Executive Vice President and Head of Research and Product Development |
| Dr. Stina Singel M.D., Ph.D. | Executive Vice President and Head of Clinical Development for Oncology |
| Joseph Kelly | Head of U.S. Commercial of Endocrinology |
| Sherrie Glass | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | 144 | Filing |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 13, 2025 | 144 | Filing |
| Aug 13, 2025 | 144 | Filing |
| Aug 13, 2025 | 6-K | Report of foreign issuer |
| Aug 13, 2025 | SCHEDULE 13G | Filing |
| Aug 12, 2025 | 144 | Filing |
| Aug 7, 2025 | 6-K | Report of foreign issuer |
| Aug 7, 2025 | 6-K | Report of foreign issuer |